Cipla Ltd.

Cipla has reported unaudited results for the first quarter ended June 30, 2011.

The company’s net profit for the quarter ended June 30, 2011 has declined marginally by 1.58% at Rs 253.34 crore as compared to Rs 257.42 crore for the corresponding quarter last year. Its income from operation has grown by 7.09% at Rs 1616.27 crore for the quarter under review from Rs 1509.22 crore for the same quarter last year.

Cipla manufactures drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions. Its products are distributed in more than 180 countries worldwide.